The company says it raised approximately $25 million in the fiscal year ended March 31, 2026. It says its cash funds the planned Phase 3 trial of urcosimod.
OKYO Pharma Limited says it sold $3,999,911 under an earlier $4,000,000 supplement and will make no more sales under it. The new program is with B. Riley Securities.
Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.
Questions about OKYO Pharma
Has OKYO Pharma raised money recently?
Our latest story on this, dated Jul 20, 2026: "OKYO Pharma files annual report, cites $22 million offering and $20.6 million cash". The story links the filing or release it is based on. Read the story.
What is the ticker symbol of OKYO Pharma?
OKYO Pharma Limited trades under the ticker OKYO on NASDAQ.
Where is OKYO Pharma listed?
OKYO Pharma Limited is listed on NASDAQ.
What is the SEC CIK of OKYO Pharma?
The SEC Central Index Key (CIK) for OKYO Pharma Limited is 1849296. Its filings are on SEC EDGAR.
How many shares does OKYO Pharma have outstanding?
52,479,527 shares as of 2026-07-15, per the cover page of its 20-F filed 2026-07-20.
Which country or territory is OKYO Pharma listed under?
Our directory records OKYO Pharma Limited under United Kingdom.
What does OKYO Pharma do?
Our directory classifies OKYO Pharma Limited as: Biotechnology. This is a directory classification, not a description of the pipeline.
What is the ISIN of OKYO Pharma?
The ISIN recorded for OKYO Pharma Limited is GG00BMFG5F62.
Does aibio.space cover OKYO Pharma?
aibio.space lists OKYO Pharma Limited among 2,820 public biotech companies and publishes its news here as stories appear.
Is OKYO Pharma profitable?
OKYO Pharma Limited reported a net loss of $4.7 million for the fiscal year ended Mar 31, 2025, and used $1.8 million of cash in operations, per its annual report to the SEC.
How much does OKYO Pharma spend on research and development?
$2.3 million in the fiscal year ended Mar 31, 2025, per its annual report.
How much cash does OKYO Pharma have?
$4.6 million in cash at Jul 31, 2025, per its 20-F.
What is the latest OKYO Pharma (OKYO) stock news?
Our latest story on OKYO Pharma, dated Jul 20, 2026: "OKYO Pharma files annual report, cites $22 million offering and $20.6 million cash". The company says it raised approximately $25 million in the fiscal year ended March 31, 2026. It says its cash funds the planned Phase 3 trial of urcosimod. Source.
How long will OKYO Pharma's cash last?
From our story of Jun 11, 2025: The audit report contains an explanatory paragraph about the company's ability to continue as a going concern. Source.
Is OKYO Pharma a smaller reporting company?
SEC records list OKYO Pharma Limited's filer category as: Non-accelerated filer<br>Emerging growth company.
Investor discussion: OKYO Pharma
Members talk about OKYO Pharma (OKYO). Reader posts, not aibio.space reporting, and not investment advice.
Rules
Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
Say whether you hold the stock. Every post states long, short or no position.
No paid or sponsored posts. Do not post for anyone who pays or rewards you.
No buy or sell calls and no price targets.
No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
No personal details and no spam. No links at all for your first 7 days as a member.
Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.
Capital-markets timeline
Financings, listing notices, splits, legal actions and other investor events at OKYO Pharma, newest first. Each line links the filing it comes from.
Set up an at-the-market program to sell shares over time. SEC Form 424B5. Source
Stock chart
Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open NASDAQ:OKYO on TradingView.
SEC filings and registration
SEC name
OKYO Pharma Ltd
CIK
1849296
Industry (SIC)
Biological Products, (No Diagnostic Substances) (2836)
US tickers
OKYO (Nasdaq)
Filer category
Non-accelerated filer<br>Emerging growth company
Business address
55 PARK LANE, LONDON, United Kingdom, W1K 1NA
Phone
44 (0) 207 495 2379
Shares outstanding
52,479,527 as of 2026-07-15 (20-F filed 2026-07-20)
Recent filings (8-K and 6-K are the company's own announcements)
Source: SEC EDGAR, retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.
Listing details
OKYO Pharma Limited is a public biotech or pharmaceutical company listed on NASDAQ under the ticker OKYO, recorded under United Kingdom. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.
Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.
Published and maintained by aibio.space. Not investment advice. How we work.
Who manages this pageThis page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio